Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.
Also called NCT05533632
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 104 participants
- Sponsor
- Registry
-
NCT05533632
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Chile
- Registry status
- Completed
Technical summary
Registry record NCT05533632. Allocation not applicable; no masking; primary purpose treatment. Start 2022-04-25 (actual); primary completion 2024-01-18 (actual). Results posted on 2025-02-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct05533632- Content hash
cad098f2f38f8678d61ccc2405681a863752c69b2dc16f997916d9100f12a287